# Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

> **NCT02715700** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV) Infection

## Interventions

- **DRUG:** Methadone
- **DRUG:** Doravirine

## Key facts

- **NCT ID:** NCT02715700
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-28
- **Primary completion:** 2016-06-13
- **Final completion:** 2016-08-15
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02715700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02715700, "Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02715700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*